Loading patent…
AssigneeWashington University
InventorsMichael Diamond, Theodore Oliphant, Christopher Doane
Estimating the term…
The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
A monoclonal antibody or an antigen binding fragment thereof that specifically binds a West Nile virus antigen.
A hybridoma cell line E16, E24, or E34, having ATCC Accession No. PTA-6050, PTA-6051, or PTA-6052, respectively.
A monoclonal antibody or an antigen binding fragment thereof that specifically binds a West Nile virus antigen, said antibody comprising a VH chain having the amino acid sequence of SEQ ID No 4, 8, or 12.
A monoclonal antibody or an antigen binding fragment thereof that specifically binds a West Nile virus antigen, said antibody comprising a VL chain having the amino acid sequence of SEQ ID No 2, 6, or 10.
Dependencies are inferred from the claim text.